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In Reply Fogelson and Leuchter have responded to our pro-
posedstagingschemefor treatment-resistantdepression (TRD)
published in JAMAPsychiatry.1Wedonot fundamentally dis-
agree with their arguments; however, we stand by our pro-
posal that psychiatry needs to move toward a more empiri-
cally based TRD definition.
Fogelson and Leuchter express concern about the lack of
evidence to support using different antidepressant classes
to improve antidepressant efficacy. In putting forward our
preliminary TRD staging model, we included both psycho-
pharmacology and psychotherapy treatments. Further, we
describe preliminary treatment recommendations for stage I
TRD,which includenonpharmacological treatments (electro-
convulsive therapyandrepetitive transcranialmagnetic stimu-
lation) as possible treatment trials for stage I TRD.
If the treatments are pharmacological, the rationale for
requiring failure of 2different classes is basedonexisting lim-
ited evidence of the predictive value of specific antidepres-
sant trial combinations in predicting future resistance. For
example, does failure to benefit from escitalopram and cita-
lopram(sameclass) convey the same informationabout future
likelihoodofbenefit as a failed response to2medications from
different classes, say escitalopram and nortriptyline? We
believe there is no compelling evidence to address this ques-
tion.Whensuggestinganarbitrary thresholdandgeneralguide-
line for defining TRD, it seems prudent to require 2 different
treatment classes,whetherwithin pharmacological interven-
tions or across the different types of intervention.
Existingdata suggest theoppositeproblem.Evidence from
acommunity referralTRDclinic foundpatientswithTRDfailed
an average of 3.6 selective serotonin reuptake inhibitor class
antidepressants,withmany failing 5 selective serotonin reup-
take inhibitors.2 Thus, many patients with TRD fail a multi-
tude of similar mechanism antidepressants for years.
Regarding their other arguments (TRD is likelymultifacto-
rial/heterogeneousandTRDmodelsbasedonnumberof failed
treatment trialswouldnot address subtypes): the authors sug-
gest that patientswithTRDandcomorbidpersonalitydisorder
or history of childhood adversity/traumamay require specific
antidepressant interventions to be considered resistant. We
agreethat inthefuture,TRDstagingwillneedrefinement ifclini-
cal features/biomarkers that predict outcome with specific
antidepressant interventions are determined. However,
presently, we do not have this level of knowledge and these
associations arenot sufficiently robust or reliable to justify the
refinements suggested by the authors.
Weconcurwith the ambitious goal of refining specific bio-
markers and clinical TRD subtypes. However, until achieved,
the severe costs of TRD treatment failure (10%per annum re-
sponse rate to standard treatments3 and high suicide risk4)
warrant a more practical and utilitarian TRD staging system
to allow research and clinical practice to progress.
Finally, Fogelson and Leuchter suggest that by highlight-
ing the number of drug trials as the primarymeasure to stage
TRD,weperpetuate “aneurochemical approach toTRD…”Our
proposed TRD model actually does the opposite. An impor-
tant goal of our model is to help psychiatrists “think outside
the box” of standard neurochemical approaches (using more
novel mechanism of action treatments, eg, ketamine, repeti-
tive transcranialmagnetic stimulation, andnovelpsychothera-
pies) relatively early on in treatment, thereby decreasing the
period of dealing with TRD.
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Are There Differences in Disruptions
of Reward Processing Between Substance Use
Disorder andGambling Disorder?
To the Editor To our knowledge, functional magnetic reso-
nance imaging (fMRI) studies todatehave reportedboth stria-
tal hypoactivations and hyperactivations during anticipation
and outcome notification of monetary rewards, making it
impossible to fit the results to one specific theory of addic-
tion. To clarify these contradicting findings, Luijtenet al1 used
meta-analyses of fMRI data to provide a valuable summary of
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results across many studies in the field of reward processing
in addiction.We acclaim this study andwould like to contrib-
ute to thediscussion about the implications of the findings by
pointing out some of the issues that need to be addressed in
future research to further advance the field.
Inevitably, studiesbrought together inameta-analysisdif-
fer, but when a group of studies is sufficiently homogeneous,
the results are thought to be robust. In the article,1 the sub-
stance use disorder (SUD) section primarily included studies
using themonetary incentive delay task (13 of 17 studies), add-
ing to the robustnessof theSUDresults.However, there is con-
siderable heterogeneity in the tasks included in the gambling
disorder (GD) section:only4of8studiesused themonetary in-
centive delay task. Other studies focused on expectancy value
coding,2 effort/motivation-relatedactivity,3 reversal learning,4
and blackjack-related wins and losses.5 Thus, although these
tasks measured aspects of reward processing, not all of them
werespecificallytailoredtocapturerewardanticipationandout-
comenotification.Additionally, the fMRI contrasts included in
the meta-analysis1 were not necessarily the contrasts of main
interest of these studies. Together, this may have resulted in
reducedpower for the includedcontrastsandactivationofbrain
areas (eg, dorsal vs ventral striatum) associated with other
aspects of reward processing assessed in these tasks. There-
fore, the results concerning the GD studies should be inter-
preted with caution, and any conclusion about differences
between SUD and GD is possibly confounded. Moreover, al-
though the authors1 alluded to disparate patterns of brain ac-
tivation between SUD andGD, thiswas not statistically tested.
All things considered, the conclusion that the differences
between SUD and GD are due to the monetary nature of the
rewards is not substantiated at this point. Moremonetary in-
centive delay studies in GDwill provide consistency in future
meta-analyses and will facilitate comparisons with SUD. We
endorse the authors’ recommendation to “go beyond the use
ofmonetary rewards in fMRI studies, eg,usingpositive scenes,
food, juice, or erotic stimuli,”1 with the ultimate goal to uni-
vocally arbitrate between theories of addiction.
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In Reply Van Holst et al provide a thoughtful comment on our
meta-analysis of functionalmagnetic resonance imaging stud-
ies investigating reward processing in addiction.1 Their letter
mainly focuses on 2 methodological points.
First, van Holst et al highlight that the tasks used in gam-
bling disorder (GD) studies are less homogeneous than those
in substance use disorder (SUD) studies. Although this is
correct—and reflects fewer studies available on GD—we
believe that contrast homogeneity, rather than task homoge-
neity, is what primarilymatters. In keepingwith this, we care-
fully selected those contrasts that capture the 2 cognitive
processesof interest inourmeta-analysis,namelymonetary re-
wardanticipationandoutcome. Incidentally, this is the reason
why someof these contrasts depart from those reported in the
original articles. It is worth emphasizing that heterogeneity is
a pervasive problem in (neuroimaging)meta-analyses that ex-
tends beyond tasks and includes heterogeneity in design effi-
ciency, data analysis, and population selection. However, task
heterogeneity is not necessarily detrimental, as the conver-
genceofactivationsdespitesuchheterogeneityensures that the
results are not due to idiosyncrasies in task design and are
generalizable across a variety of paradigms.2
Second, as vanHolst et al correctly point out, the SUDand
GD populations were not directly compared. The main rea-
son is that these populations originated from different stud-
ies andwere thus unlikely to bematched. In addition, our ra-
tionale for including both SUD andGD studies was the search
for similarities, rather than differences, in brain activations.
As a result, we agree with van Holst et al that differences
uncovered by ourmeta-analysis between brainmaps for SUD
andGDstudies are inherently qualitative and should be inter-
preted with caution.
Yet, it isofcrucial relevancetoexploreneurobiological simi-
larities anddifferencesbetweenbehavioral addictions, suchas
GD,andsubstanceaddictionsbecausethiscanshedlightonsev-
eral highly debated issues. First, there is a growing number of
problematic behaviors being regarded as potential behavioral
addictions including problematic internet use, binge eating,
compulsivebuying, andcompulsive sexual activities.3Accord-
ingly, in the DSM-5, a chapter on substance use and addictive
disorders was included containing GD as a behavioral addic-
tion and internet gaming disorder as a “condition for further
study.” Unraveling the neural mechanisms underlying these
problematicbehaviorscouldhelprefinetheboundariesanddefi-
nition of behavioral addictions. Second, substance and behav-
ioral addictions have partly similar diagnostic characteristics,
such as craving, diminishedbehavioral control, tolerance, and
withdrawal-like symptoms. It isunclearwhether thishomoge-
neity in symptomsalso reflects sharedneurobiologicalmecha-
nisms. This question is clinically relevant, as treatment ap-
proachesforSUDarecurrentlyadaptedandappliedtobehavioral
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addictions including GD.4,5 Neuroimaging studies could shed
light on the sensibility of such an approach and could poten-
tially guide future treatment development for substance and
behavioral addictions.
In conclusion,we fully agreewithvanHolst et al thatmore
studies investigating reward processing in behavioral addic-
tions are needed to further advance our understanding of
shared and distinct neural mechanisms contributing to SUD
and behavioral addictions.
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First-Episode Schizophrenia andDiabetes Risk
To the Editor In their article in JAMA Psychiatry, Pillinger and
colleagues1 shed lightontheassociationbetweenschizophrenia
and an increased risk for type 2diabetes, showing that patients
areat increasedriskfordiabetes fromtheonsetof illnessandnot
onlyasaconsequenceoflong-termtreatmentandchronicillness.
But thesedataalsobeg thequestionas towhythere isabnormal
glucosemetabolismandbioenergetics in the disorder.
The first indication of abnormal energy generation in
schizophrenia, increased lactate and decreased glutathione,
wasnotedasearlyas 1934.2Mitochondrial function isnowcon-
firmed to be abnormal in schizophrenia and drives part of the
pathophysiologyof thedisorder aswell as comorbidities such
as glucose dysregulation. Numerous molecular functional
neuroimaging studies have connected compromised brain
energy metabolism and oxidative stress due to mitochon-
drial dysfunctionwith thepathophysiologyof schizophrenia.2
Type 2 diabetes is a complex metabolic disease due to
pancreatic β-cell dysfunction and is associated with obesity,
insulin resistance, and hypoinsulinemia. Impaired glucose
homeostasis is associated with compromised mitochondrial
biogenesis and function.3
Because long-termantipsychoticuse increases the risk for
type 2diabetes, this is a confounding factor in the association
of impaired glucose homeostasis and schizophrenia. Being
able to remove this bias by analyzing individuals with first-
episode schizophrenia allows observation of early alterations
in glucose homeostasis in this subgroup. This finding of
abnormal glucose homeostasis at disease onset supports the
concept that bioenergetic dysregulation driven bymitochon-
drial dysfunctionmay represent a commonmolecularmecha-
nism that underpins both schizophrenia and type 2 diabetes,
and explains, at least in part, their frequent co-occurrence.
In summary,Pillinger andcolleagues’ study1 createsan im-
perative for new research to determine themolecularmecha-
nism(s) defining the potentially overlapping relationship
between schizophrenia and type 2 diabetes. Mitochondrial
dysfunction is a logical target. The mechanistic roads to mi-
tochondrialdysfunction includeotherbiologicalpathways that
are linked to diabetes, schizophrenia, and other comorbid
disorders.4 Defining the molecular pathways that lead to
mitochondrial dysfunction has the potential to enhance our
understanding of the underlying pathophysiology of schizo-
phrenia and potentially define novel treatment targets.
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To the Editor In their recent systematic review and meta-
analysis, Pillinger and colleagues1 examined whether indi-
vidualswith first-episode schizophrenia exhibit an “inherent
risk” for type 2 diabetes. Their study has several limitations,
mostnotably themethodological limitationsof thestudiescon-
tributing to the meta-analysis as well as an overinterpreta-
tion of results.
Thestudies included in themeta-analysisappear tobecon-
venience samples with small sample sizes (10-120 patients),
rather than representative or randomsamples that could pro-
tect against sampling bias. Despite no prior evidence for
de novo β-cell failure or ketoacidosis in antipsychotic-naive
patients, the analysis focused on diabetes diagnostic criteria
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